Global Meningococcal Infections Vaccine Market Insights, Forecast to 2025

Description

The global Meningococcal Infections Vaccine market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Meningococcal Infections Vaccine market based on company, product type, end user and key regions.

This report studies the global market size of Meningococcal Infections Vaccine in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Meningococcal Infections Vaccine in these regions.
This research report categorizes the global Meningococcal Infections Vaccine market by top players/brands, region, type and end user. This report also studies the global Meningococcal Infections Vaccine market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Sanofi-Pasteur
Beijing Tiantan Biological Products
Shanghai Institute of Biological Products
Wuhan Institute of Biological Products
Lanzhou Institute of Biological Products
Hualan Biological Engineering
Chongqing Zhifei Biological Products
Zhejiang Tianyuan Bio-Pharmaceutical
Walvax Biotechnology
Royal(Wuxi) Bio-Pharmaceutical

Market size by Product
Meningococcal Conjugate Vaccines
Meningococcal Polysaccharide Vaccine
Serogroup B Meningococcal Vaccine
Market size by End User
Children
Preteens/Teens
Adults

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Meningococcal Infections Vaccine market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Meningococcal Infections Vaccine market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Meningococcal Infections Vaccine companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Meningococcal Infections Vaccine submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Meningococcal Infections Vaccine are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Doses). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Meningococcal Infections Vaccine market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

TABLE OF CONTENT

Table of Contents

1 Study Coverage
1.1 Meningococcal Infections Vaccine Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Meningococcal Infections Vaccine Market Size Growth Rate by Product
1.4.2 Meningococcal Conjugate Vaccines
1.4.3 Meningococcal Polysaccharide Vaccine
1.4.4 Serogroup B Meningococcal Vaccine
1.5 Market by End User
1.5.1 Global Meningococcal Infections Vaccine Market Size Growth Rate by End User
1.5.2 Children
1.5.3 Preteens/Teens
1.5.4 Adults
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Meningococcal Infections Vaccine Market Size
2.1.1 Global Meningococcal Infections Vaccine Revenue 2014-2025
2.1.2 Global Meningococcal Infections Vaccine Sales 2014-2025
2.2 Meningococcal Infections Vaccine Growth Rate by Regions
2.2.1 Global Meningococcal Infections Vaccine Sales by Regions
2.2.2 Global Meningococcal Infections Vaccine Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Meningococcal Infections Vaccine Sales by Manufacturers
3.1.1 Meningococcal Infections Vaccine Sales by Manufacturers
3.1.2 Meningococcal Infections Vaccine Sales Market Share by Manufacturers
3.1.3 Global Meningococcal Infections Vaccine Market Concentration Ratio (CR5 and HHI)
3.2 Meningococcal Infections Vaccine Revenue by Manufacturers
3.2.1 Meningococcal Infections Vaccine Revenue by Manufacturers (2014-2019)
3.2.2 Meningococcal Infections Vaccine Revenue Share by Manufacturers (2014-2019)
3.3 Meningococcal Infections Vaccine Price by Manufacturers
3.4 Meningococcal Infections Vaccine Manufacturing Base Distribution, Product Types
3.4.1 Meningococcal Infections Vaccine Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Meningococcal Infections Vaccine Product Type
3.4.3 Date of International Manufacturers Enter into Meningococcal Infections Vaccine Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
4.1 Global Meningococcal Infections Vaccine Sales by Product
4.2 Global Meningococcal Infections Vaccine Revenue by Product
4.3 Meningococcal Infections Vaccine Price by Product

5 Breakdown Data by End User
5.1 Overview
5.2 Global Meningococcal Infections Vaccine Breakdown Data by End User

6 North America
6.1 North America Meningococcal Infections Vaccine by Countries
6.1.1 North America Meningococcal Infections Vaccine Sales by Countries
6.1.2 North America Meningococcal Infections Vaccine Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Meningococcal Infections Vaccine by Product
6.3 North America Meningococcal Infections Vaccine by End User

7 Europe
7.1 Europe Meningococcal Infections Vaccine by Countries
7.1.1 Europe Meningococcal Infections Vaccine Sales by Countries
7.1.2 Europe Meningococcal Infections Vaccine Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Meningococcal Infections Vaccine by Product
7.3 Europe Meningococcal Infections Vaccine by End User

8 Asia Pacific
8.1 Asia Pacific Meningococcal Infections Vaccine by Countries
8.1.1 Asia Pacific Meningococcal Infections Vaccine Sales by Countries
8.1.2 Asia Pacific Meningococcal Infections Vaccine Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Meningococcal Infections Vaccine by Product
8.3 Asia Pacific Meningococcal Infections Vaccine by End User

9 Central & South America
9.1 Central & South America Meningococcal Infections Vaccine by Countries
9.1.1 Central & South America Meningococcal Infections Vaccine Sales by Countries
9.1.2 Central & South America Meningococcal Infections Vaccine Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Meningococcal Infections Vaccine by Product
9.3 Central & South America Meningococcal Infections Vaccine by End User

10 Middle East and Africa
10.1 Middle East and Africa Meningococcal Infections Vaccine by Countries
10.1.1 Middle East and Africa Meningococcal Infections Vaccine Sales by Countries
10.1.2 Middle East and Africa Meningococcal Infections Vaccine Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Meningococcal Infections Vaccine by Product
10.3 Middle East and Africa Meningococcal Infections Vaccine by End User

11 Company Profiles
11.1 Sanofi-Pasteur
11.1.1 Sanofi-Pasteur Company Details
11.1.2 Company Business Overview
11.1.3 Sanofi-Pasteur Meningococcal Infections Vaccine Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Sanofi-Pasteur Meningococcal Infections Vaccine Products Offered
11.1.5 Sanofi-Pasteur Recent Development
11.2 Beijing Tiantan Biological Products
11.2.1 Beijing Tiantan Biological Products Company Details
11.2.2 Company Business Overview
11.2.3 Beijing Tiantan Biological Products Meningococcal Infections Vaccine Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Beijing Tiantan Biological Products Meningococcal Infections Vaccine Products Offered
11.2.5 Beijing Tiantan Biological Products Recent Development
11.3 Shanghai Institute of Biological Products
11.3.1 Shanghai Institute of Biological Products Company Details
11.3.2 Company Business Overview
11.3.3 Shanghai Institute of Biological Products Meningococcal Infections Vaccine Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Shanghai Institute of Biological Products Meningococcal Infections Vaccine Products Offered
11.3.5 Shanghai Institute of Biological Products Recent Development
11.4 Wuhan Institute of Biological Products
11.4.1 Wuhan Institute of Biological Products Company Details
11.4.2 Company Business Overview
11.4.3 Wuhan Institute of Biological Products Meningococcal Infections Vaccine Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Wuhan Institute of Biological Products Meningococcal Infections Vaccine Products Offered
11.4.5 Wuhan Institute of Biological Products Recent Development
11.5 Lanzhou Institute of Biological Products
11.5.1 Lanzhou Institute of Biological Products Company Details
11.5.2 Company Business Overview
11.5.3 Lanzhou Institute of Biological Products Meningococcal Infections Vaccine Sales, Revenue and Gross Margin (2014-2019)
11.5.4 Lanzhou Institute of Biological Products Meningococcal Infections Vaccine Products Offered
11.5.5 Lanzhou Institute of Biological Products Recent Development
11.6 Hualan Biological Engineering
11.6.1 Hualan Biological Engineering Company Details
11.6.2 Company Business Overview
11.6.3 Hualan Biological Engineering Meningococcal Infections Vaccine Sales, Revenue and Gross Margin (2014-2019)
11.6.4 Hualan Biological Engineering Meningococcal Infections Vaccine Products Offered
11.6.5 Hualan Biological Engineering Recent Development
11.7 Chongqing Zhifei Biological Products
11.7.1 Chongqing Zhifei Biological Products Company Details
11.7.2 Company Business Overview
11.7.3 Chongqing Zhifei Biological Products Meningococcal Infections Vaccine Sales, Revenue and Gross Margin (2014-2019)
11.7.4 Chongqing Zhifei Biological Products Meningococcal Infections Vaccine Products Offered
11.7.5 Chongqing Zhifei Biological Products Recent Development
11.8 Zhejiang Tianyuan Bio-Pharmaceutical
11.8.1 Zhejiang Tianyuan Bio-Pharmaceutical Company Details
11.8.2 Company Business Overview
11.8.3 Zhejiang Tianyuan Bio-Pharmaceutical Meningococcal Infections Vaccine Sales, Revenue and Gross Margin (2014-2019)
11.8.4 Zhejiang Tianyuan Bio-Pharmaceutical Meningococcal Infections Vaccine Products Offered
11.8.5 Zhejiang Tianyuan Bio-Pharmaceutical Recent Development
11.9 Walvax Biotechnology
11.9.1 Walvax Biotechnology Company Details
11.9.2 Company Business Overview
11.9.3 Walvax Biotechnology Meningococcal Infections Vaccine Sales, Revenue and Gross Margin (2014-2019)
11.9.4 Walvax Biotechnology Meningococcal Infections Vaccine Products Offered
11.9.5 Walvax Biotechnology Recent Development
11.10 Royal(Wuxi) Bio-Pharmaceutical
11.10.1 Royal(Wuxi) Bio-Pharmaceutical Company Details
11.10.2 Company Business Overview
11.10.3 Royal(Wuxi) Bio-Pharmaceutical Meningococcal Infections Vaccine Sales, Revenue and Gross Margin (2014-2019)
11.10.4 Royal(Wuxi) Bio-Pharmaceutical Meningococcal Infections Vaccine Products Offered
11.10.5 Royal(Wuxi) Bio-Pharmaceutical Recent Development

12 Future Forecast
12.1 Meningococcal Infections Vaccine Market Forecast by Regions
12.1.1 Global Meningococcal Infections Vaccine Sales Forecast by Regions 2019-2025
12.1.2 Global Meningococcal Infections Vaccine Revenue Forecast by Regions 2019-2025
12.2 Meningococcal Infections Vaccine Market Forecast by Product
12.2.1 Global Meningococcal Infections Vaccine Sales Forecast by Product 2019-2025
12.2.2 Global Meningococcal Infections Vaccine Revenue Forecast by Product 2019-2025
12.3 Meningococcal Infections Vaccine Market Forecast by End User
12.4 North America Meningococcal Infections Vaccine Forecast
12.5 Europe Meningococcal Infections Vaccine Forecast
12.6 Asia Pacific Meningococcal Infections Vaccine Forecast
12.7 Central & South America Meningococcal Infections Vaccine Forecast
12.8 Middle East and Africa Meningococcal Infections Vaccine Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Meningococcal Infections Vaccine Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

Choose License Type

Checkout Inquiry Sample